L'afatinib, un nouveau médicament dans le cancer bronchique

Jérôme Sicard; Jean Baptiste Rey; Florian Scotté; Laurent Mortier

doi:10.1016/j.actpha.2015.03.010

L'afatinib, un nouveau médicament dans le cancer bronchique

Jérôme Sicard, Jean Baptiste Rey, Florian Scotté, Laurent Mortier

Résultats de recherche: Contribution à un journal › Article 'review' › Revue par des pairs

Résumé

Afatinib is an irreversible oral tyrosine kinase inhibitor, which blocks the receptors from the ErbB family. Its superiority over leading chemotherapy treatments in terms of progression-free survival and overall survival in patients who are carriers of exon 19 deletion in non small cell lung cancers with EGFR mutations has been proven. Its administration has been associated with side affects found with the class of tyrosine kinase inhibitors, the treatment of which includes preventive and symptomatic measures which must be explained to the patient, along with their impact on compliance with the treatment.

Titre traduit de la contribution	Afatinib, a new drug for lung cancer
langue originale	Français
Pages (de - à)	42-45
Nombre de pages	4
journal	Actualites Pharmaceutiques
Volume	54
Numéro de publication	546
Les DOIs	https://doi.org/10.1016/j.actpha.2015.03.010
état	Publié - 1 mai 2015
Modification externe	Oui

mots-clés

afatinib
non small cell lung cancer
targeted therapy
tyrosine kinase inhibitor

Accès au document

10.1016/j.actpha.2015.03.010

Autres fichiers et liens

Lien vers la publication dans Scopus

Contient cette citation

@article{68df7e3ccc0f453ca2546c3b2e0777ee,

title = "L'afatinib, un nouveau m{\'e}dicament dans le cancer bronchique",

abstract = "Afatinib is an irreversible oral tyrosine kinase inhibitor, which blocks the receptors from the ErbB family. Its superiority over leading chemotherapy treatments in terms of progression-free survival and overall survival in patients who are carriers of exon 19 deletion in non small cell lung cancers with EGFR mutations has been proven. Its administration has been associated with side affects found with the class of tyrosine kinase inhibitors, the treatment of which includes preventive and symptomatic measures which must be explained to the patient, along with their impact on compliance with the treatment.",

keywords = "afatinib, non small cell lung cancer, targeted therapy, tyrosine kinase inhibitor",

author = "J{\'e}r{\^o}me Sicard and Rey, {Jean Baptiste} and Florian Scott{\'e} and Laurent Mortier",

note = "Publisher Copyright: {\textcopyright} 2015 Elsevier Masson SAS.",

year = "2015",

month = may,

day = "1",

doi = "10.1016/j.actpha.2015.03.010",

language = "Fran{\c c}ais",

volume = "54",

pages = "42--45",

journal = "Actualites Pharmaceutiques",

issn = "0515-3700",

number = "546",

}

TY - JOUR

T1 - L'afatinib, un nouveau médicament dans le cancer bronchique

AU - Sicard, Jérôme

AU - Rey, Jean Baptiste

AU - Scotté, Florian

AU - Mortier, Laurent

PY - 2015/5/1

Y1 - 2015/5/1

N2 - Afatinib is an irreversible oral tyrosine kinase inhibitor, which blocks the receptors from the ErbB family. Its superiority over leading chemotherapy treatments in terms of progression-free survival and overall survival in patients who are carriers of exon 19 deletion in non small cell lung cancers with EGFR mutations has been proven. Its administration has been associated with side affects found with the class of tyrosine kinase inhibitors, the treatment of which includes preventive and symptomatic measures which must be explained to the patient, along with their impact on compliance with the treatment.

AB - Afatinib is an irreversible oral tyrosine kinase inhibitor, which blocks the receptors from the ErbB family. Its superiority over leading chemotherapy treatments in terms of progression-free survival and overall survival in patients who are carriers of exon 19 deletion in non small cell lung cancers with EGFR mutations has been proven. Its administration has been associated with side affects found with the class of tyrosine kinase inhibitors, the treatment of which includes preventive and symptomatic measures which must be explained to the patient, along with their impact on compliance with the treatment.

KW - afatinib

KW - non small cell lung cancer

KW - targeted therapy

KW - tyrosine kinase inhibitor

UR - http://www.scopus.com/inward/record.url?scp=84929246520&partnerID=8YFLogxK

U2 - 10.1016/j.actpha.2015.03.010

DO - 10.1016/j.actpha.2015.03.010

M3 - Article 'review'

AN - SCOPUS:84929246520

SN - 0515-3700

VL - 54

SP - 42

EP - 45

JO - Actualites Pharmaceutiques

JF - Actualites Pharmaceutiques

IS - 546

ER -